Login / Signup

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study.

René J BoosmanNikki de RouwAlwin D R HuitemaJacobus A BurgersRob Ter Heine
Published in: British journal of clinical pharmacology (2022)
We show that test dosing of pemetrexed is feasible, but there seems no added value for a low test dosing in the dose individualization of pemetrexed.
Keyphrases
  • small cell lung cancer
  • advanced non small cell lung cancer
  • epidermal growth factor receptor